BioNTech, MediLink to resume trial enrollment for HER3 antibody-drug conjugate after FDA pause

Lei Lei Wu

News Reporter

Amber Tong

The FDA on Thursday lifted a partial clinical hold on an early-stage study of a HER3-targeting antibody-drug conjugate that BioNTech is developing with China-based MediLink …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BioNTech, MediLink to resume trial enrollment for HER3 antibody-drug conjugate after FDA pause

Lei Lei Wu

News Reporter

Amber Tong

Sign up to read this article for free.

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?

BioN­Tech, MediLink to re­sume tri­al en­roll­ment for HER3 an­ti­body-drug con­ju­gate af­ter FDA pause

News Reporter

Sign up to read this article for free.

BioNTech, MediLink to resume trial enrollment for HER3 antibody-drug conjugate after FDA pause